Risk stratification of major adverse cardiovascular events in heart failure patients undergoing coronary artery bypass grafting: an observational multicenter prospective study (PROFILE-HF)

Introduction. Coronary artery bypass grafting (CABG) is a primary treatment for patients with coronary artery disease (CAD) and chronic heart failure (CHF) with multivessel atherosclerosis of the coronary arteries. However, major clinical studies demonstrate a persistent high risk of adverse cardiovascular events in this cohort, even after revascularization. Growth Differentiation Factor 15 (GDF-15), according to several studies, has high prognostic value in patients with CHF and CAD, including those who have undergone CABG. This finding requires confirmation in specially designed prospective multicenter studies.

Aim: To present a study protocol with the primary aim of developing a method for assessing the risk of adverse cardiovascular events in patients with coronary artery disease (CAD) and chronic heart failure (CHF) who have undergone coronary artery bypass grafting (CABG), taking into account preoperative growth differentiation factor-15 (GDF-15) levels.

Material and Methods. This is a multicenter, observational, prospective study of the clinical course and outcomes of patients with CAD and CHF who have undergone CABG. To ensure a representative sample, at least 160 patients will be enrolled. The study will have a 12-month follow-up period.

Expected results. The study will include collecting patient complaints and anamnesis, performing a physical examination, a six minute walk test, and analyzing the results of general clinical laboratory and instrumental examinations. GDF-15 concentrations will be analyzed centrally at the Cardiology Research Institute, Tomsk NRMC laboratory. Treatment adherence will be assessed using the Morisky-Green questionnaire at the enrollment visit and after 12 months of follow-up. The study will be followed for 12 months. Prospective follow-up will assess the development of a combined primary and secondary endpoint, including death and adverse cardiovascular events.

Conclusion. PROFILE-HF is the first multicenter prospective study specifically designed to evaluate the prognostic significance of preoperative GDF-15 concentrations in patients with coronary artery disease and CHF who underwent CABG.

1. Polyakov D.S., Fomin I.V., Belenkov Y.N., et al. Chronic heart failure in the Russian Federation: what has changed over 20 years of follow-up? Results of the EPOCH-CHF study. Kardiologiia. 2021;61(4):4–14. (In Russ.). DOI: 10.18087/cardio.2021.4.n1628 EDN: WSZNFS

2. Shlyakhto E.V., Belenkov Yu.N., Boytsov S.A., et al. Characteristics and outcomes in outpatients with heart failure in Russia: results of a large-scale prospective observational multicenter registry study PRIORITY-HF. Russian Journal of Cardiology. 2025;30(11S):6516. (In Russ.). DOI: 10.15829/1560-4071-2025-6516. EDN: DZOXMG

3. Garganeeva A.A., Tukish O.V., Vitt K.N., et al. Chronic Heart Failure in Patients Hospitalized in 2002 and 2021: Comparative Analysis of Prevalence, Clinical Course and Drug Therapy. Kardiologiia. 2024;64(3):3–10. (In Russ.). DOI: 10.18087/cardio.2024.3.n2595 EDN: EWOGWO

4. Velazquez E.J., Lee K.L., Deja M.A., et al. STICH Investigators. Coronary-artery bypass surgery in patients with left ventricular dysfunction. N. Engl. J. Med. 2011;364(17):1607–1616. DOI: 10.1056/NEJMoa1100356

5. Marui A., Nishiwaki N., Komiya T., et al. CREDO-Kyoto CABG Registry Cohort-2 Investigators. Comparison of 5-Year Outcomes After Coronary Artery Bypass Grafting in Heart Failure Patients With Versus Without Preserved Left Ventricular Ejection Fraction (from the CREDO-Kyoto CABG Registry Cohort-2). Am. J. Cardiol. 2015;116(4):580–586. DOI: 10.1016/j.amjcard.2015.05.020

6. Ozdemir E., Stavileci B., Ozdemir B., et al. The association between growth differentiation factor 15 and presence and severity of coronary atherosclerosis. Adv. Med. Sci. 2024;69(1):56–60. DOI: 10.1016/j.advms.2024.02.003

7. Mourouzis K., Siasos G., Bozini N., et al. Association of Growth Differentiation Factor 15 with Arterial Stiffness and Endothelial Function in Subpopulations of Patients with Coronary Artery Disease: A Proof-of-Concept Study. Recent. Adv. Inflamm. Allergy Drug Discov. 2022;16(2):107–115. DOI: 10.2174/2772270817666221104120923

8. Alieva A.M., Reznik E.V., Pinchuk T.V., et al. Growth Differentiation Factor-15 (GDF-15) is a Biological Marker in Heart Failure. The Russian Archives of Internal Medicine. 2023;13(1):14–23. DOI: 10.20514/2226-6704-2023-13-1-14-23 EDN: DHDDPP

9. Zakharyan E.A. Interrelation of growth/differentiation factor-15 level with laboratory and clinical and functional parameters of patients with coronary artery disease. Cardiovascular Therapy and Prevention. 2023;22(5):3549. (In Russ.) DOI: 10.15829/1728-8800-2023-3549 EDN: XTIBWI

10. Kuzheleva E.A., Garganeeva A.A., Tukish O.V. Risk stratification of adverse cardiovascular events in patients with chronic heart failure and coronary artery disease undergoing surgical myocardial revascularization. Siberian Journal of Clinical and Experimental Medicine. 2026;41(1):149–160. (In Russ.) DOI: 10.29001/2073-8552-2026-41-1-149-160 EDN: KTHACD

11. Anand I.S., Kempf T., Rector T.S., et al. Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure Trial. Circulation. 2010;122(14):1387–1395. DOI: 10.1161/CIRCULATIONAHA.109.928846

12. Bouabdallaoui N., Claggett B., Zile M.R., et al. PARADIGM-HF Investigators and Committees. Growth differentiation factor-15 is not modified by sacubitril/valsartan and is an independent marker of risk in patients with heart failure and reduced ejection fraction: the PARADIGM-HF trial. Eur. J. Heart Fail. 2018;20(12):1701–1709. DOI: 10.1002/ejhf.1301

13. Collet J.P., Thiele H., Barbato E., et al. ESC Scientific Document Group. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur. Heart J. 2024;45(5):404–405. DOI: 10.1093/eurheartj/ehad879

14. Wollert K.C., Kempf T., Peter T., et al. Prognostic value of growth-differentiation factor-15 in patients with non-ST-elevation acute coronary syndrome. Circulation. 2007;115(8):962–71. DOI: 10.1161/CIRCULATIONAHA.106.650846

15. Garganeeva A., Kuzheleva E., Tukish O., et al. Predictors of Adverse Cardiovascular Events After CABG in Patients with Previous Heart Failure. Life (Basel). 2025;15(3):387. DOI: 10.3390/life15030387

16. Baek S.J., Kim K.S., Nixon J.B., et al. Cyclooxygenase inhibitors regulate the expression of a TGF-beta superfamily member that has proapoptotic and antitumorigenic activities. Mol. Pharmacol. 2001;59(4):901–908. DOI: 10.1016/S0026-895X(24)09260-5

17. Silva-Bermudez L.S., Klüter H., Kzhyshkowska J.G. Macrophages as a Source and Target of GDF-15. Int. J. Mol. Sci. 2024;25(13):7313. DOI: 10.3390/ijms25137313

18. Groarke J.D., Crawford J., Collins S.M., et al. Ponsegromab for the Treatment of Cancer Cachexia. N. Engl. J. Med. 2024;391(24):2291–2303. DOI: 10.1056/NEJMoa2409515